Accelerating materials property predictions using machine learning G Pilania, C Wang, X Jiang, S Rajasekaran, R Ramprasad Scientific reports 3 (1), 2810, 2013 | 788 | 2013 |
A new class of flexible link functions with application to species co-occurrence in cape floristic region X Jiang, DK Dey, R Prunier, AM Wilson, KE Holsinger The Annals of Applied Statistics, 2180-2204, 2013 | 49 | 2013 |
Tarlatamab for patients with previously treated small-cell lung cancer MJ Ahn, BC Cho, E Felip, I Korantzis, K Ohashi, M Majem, O Juan-Vidal, ... New England Journal of Medicine 389 (22), 2063-2075, 2023 | 38 | 2023 |
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary … BA Warady, JN Iles, G Ariceta, B Dehmel, G Hidalgo, X Jiang, B Laskin, ... Pediatric Nephrology 34, 475-486, 2019 | 33 | 2019 |
Analyzing basket trials under multisource exchangeability assumptions MJ Kane, N Chen, AM Kaizer, X Jiang, HA Xia, BP Hobbs arXiv preprint arXiv:1908.00618, 2019 | 8 | 2019 |
Binary state space mixed models with flexible link functions: a case study on deep brain stimulation on attention reaction time CA Abanto-Valle, DK Dey, X Jiang Statistics and Its Interface 8 (2), 187-194, 2015 | 8 | 2015 |
Bayesian adaptive design for concurrent trials involving biologically related diseases MA Psioda, HA Xia, X Jiang, J Xu, JG Ibrahim Biostatistics 23 (3), 1007-1022, 2022 | 5 | 2022 |
A survival mediation model with Bayesian model averaging J Zhou, X Jiang, H Amy Xia, P Wei, BP Hobbs Statistical Methods in Medical Research 30 (11), 2413-2427, 2021 | 5 | 2021 |
Analyzing basket trials under multisource exchangeability assumptions MJ Kane, N Chen, AM Kaizer, X Jiang, HA Xia, BP Hobbs The R Journal 12 (2), 342-358, 2021 | 5 | 2021 |
Predicting outcomes of phase iii oncology trials with bayesian mediation modeling of tumor response J Zhou, X Jiang, HA Xia, P Wei, BP Hobbs Statistics in Medicine 41 (4), 751-768, 2022 | 4 | 2022 |
Use of alternative designs and data sources for pediatric trials F Cooner, M Gamalo-Siebers, A Xia, A Gao, S Ruan, T Jiang, ... Statistics in Biopharmaceutical Research 12 (2), 210-223, 2020 | 4 | 2020 |
LBA92 Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study L Paz-Ares, MJ Ahn, E Felip, S Handzhiev, I Korantzis, H Izumi, K Ohashi, ... Annals of Oncology 34, S1333-S1334, 2023 | 3 | 2023 |
LEAP: The latent exchangeability prior for borrowing information from historical data EM Alt, X Chang, X Jiang, Q Liu, M Mo, HA Xia, JG Ibrahim arXiv preprint arXiv:2303.05223, 2023 | 2 | 2023 |
Symmetric power link with ordinal response model X Jiang, DK Dey Current Trends in Bayesian Methodology with Applications, 2015 | 2 | 2015 |
EP13. 07-03 Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy H Borghaei, X Pundole, E Anderson, G Bebb, T Jiang, M Pastel, ... Journal of Thoracic Oncology 18 (11), S706-S707, 2023 | 1 | 2023 |
Landmark mediation survival analysis using longitudinal surrogate J Zhou, X Jiang, HA Xia, BP Hobbs, P Wei Frontiers in Oncology 12, 999324, 2023 | 1 | 2023 |
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study H Borghaei, X Pundole, L Sangaré, E Anderson, G Bebb, T Jiang, ... Lung Cancer, 107819, 2024 | | 2024 |
P2. 17-01 Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer H Borghaei, J Shaw, X Pundole, A Balasubramanian, E Anderson, ... Journal of Thoracic Oncology 18 (11), S377-S378, 2023 | | 2023 |
508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study L Paz-Ares, MJ Ahn, E Felip, S Handzhiev, I Korantzis, H Izumi, K Ohashi, ... Annals of Oncology 34, S1664-S1665, 2023 | | 2023 |
Clinical cancer trials are designed to collect radiographic measurements of each patient's baseline and residual tumor burden at regular intervals over the course of study. For … J Zhou, X Jiang, HA Xia, BP Hobbs Advances in mathematical and computational oncology, volume III, 269, 2023 | | 2023 |